Keyphrases
1,2,3-Triazolyl
18%
5′-monophosphate
18%
7-transmembrane
18%
A1 Receptor
18%
Adenosine 3′
18%
Adrenergic Receptors
63%
Allosteric Ligands
18%
Allosteric Modulator
41%
Allosteric Pocket
18%
Benzene
23%
Binding Pocket
24%
Binding Site
39%
C-terminal Tail
18%
CRTH2
18%
Cyclic Adenosine Monophosphate (cAMP)
18%
Cysteine-rich Domain
18%
Downstream Signaling
18%
Drug Discovery
18%
G Protein
41%
G Protein-coupled Receptor
63%
Glucagon-like
18%
High-throughput Screening Assays
18%
Hydrochloride
18%
Imidazole Analogues
18%
Ligand-receptor Binding
18%
Metabotropic Glutamate Receptor
62%
Metabotropic Glutamate Receptor 5 (mGluR5)
62%
Metabotropic Glutamate Receptor Subtype 4 (mGlu4)
18%
Methyl
47%
Molecular Determinants
18%
Molecular Pharmacology
18%
Molecular Therapeutics
18%
Morphinan
18%
Negative Allosteric Modulator
24%
Peptidomimetics
18%
Pharmacological Characterization
23%
Pharmacological Model
18%
Pharmacological Studies
18%
Phenylethynyl
47%
Phosphodiesterase Inhibitors
18%
Positive Allosteric Modulation
18%
Protein Kinase C Activation
18%
Pyridine
47%
Pyrimidine Derivatives
18%
Ramatroban
18%
Signaling Cascades
18%
Structural Insights
56%
Surnames
18%
Therapeutic Potential
18%
Venus Flytrap
18%
Biochemistry, Genetics and Molecular Biology
Adrenergic Receptor
82%
Agonist
34%
Allosteric Regulation
18%
Binding Site
22%
C-Terminus
27%
calcium activated,phospholipid dependent protein kinase
18%
Complex Formation
18%
Conformational Change
15%
Crystal Structure
60%
Cyclic Adenosine Monophosphate
47%
Cysteine
18%
Docking (Molecular)
18%
G Protein
56%
G Protein Coupled Receptor
100%
Glucagon-Like Peptide 1 Receptor
18%
Glucagon-Like Peptide-1
18%
Glutamate Receptor
37%
High Throughput Screening
18%
Ligand Binding
28%
Metabotropic Glutamate Receptor 4
18%
Mutagenesis
18%
Opioid Receptor
18%
Peptidomimetic
18%
Phosphodiesterase
18%
Protein Complexes
37%
Pharmacology, Toxicology and Pharmaceutical Science
2 Methyl 6 (Phenylethynyl)pyridine
37%
Adenosine
18%
Adrenergic Receptor
24%
Allosteric Modulator
37%
Amino Acid
18%
AMPA Receptor
18%
Binding Site
18%
Drug Discovery
28%
G Protein Coupled Receptor
38%
Glucagon-Like Peptide 1 Receptor
18%
Glucagon-Like Peptide-1
16%
Glutamate Receptor
56%
High-Throughput Screening
18%
Metabotropic Receptor
18%
Metabotropic Receptor 4
18%
Metabotropic Receptor 5
18%
Metabotropic Receptor Agonist
18%
Molecular Pharmacology
18%
Mutagenesis
18%
Neurologic Disease
28%
Opiate Receptor
18%
Phosphodiesterase Inhibitor
18%
Ramatroban
15%
Receptor
53%
Thiazole
18%
